PF-Atlas › Clinical Trials › NCT07528703

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants

RC010 Inhalation Powder · Phase 1

Registry ID
NCT07528703
Phase
Phase 1
Status
Not yet recruiting
Drug / intervention
RC010 Inhalation Powder
Sponsor
Nanjing Reju Therapeutics Co., Ltd
Start
2026-04
Enrollment
42
Locations
1

About this trial

This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of RC010 in healthy adult volunteers. RC010 is a small-molecule drug , being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability and pharmacokinetics of RC010 after Single ascending doses .

View NCT07528703 on ClinicalTrials.gov →

Explore related

All RC010 Inhalation Powder trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07528703 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.